Clinical Presentation, Treatment Outcomes, and Resistance-related Factors in South American Women with Low-risk Postmolar Gestational Trophoblastic Neoplasia

Apresentação clínica, resultados do tratamento e fatores relacionados à resistência em mulheres sul-americanas com neoplasia trofoblástica gestacional pós-molar de baixo risco

Luz Angela Correa Ramírez1,2, Izildinha Maestá3, María Inés Bianconi4, Gustavo Jankilevich4, Silvina Otero4, Carlos Raúl Villegas Mejía5, Rafael Cortés-Charry6, Kevin M. Elias7, Neil S. Horowitz7, Michael Seckl8, Ross S. Berkowitz7

1 Postgraduation Program in Tocogynecology of Botucatu Medical School, São Paulo State University Julio de Mesquita Filho - UNESP, Support Program for Foreign Doctoral Students (PAEDEx/UNESP) Botucatu, SP, Brazil
2 Clinical Department, Universidad de Caldas, Manizales, Caldas, Colombia
3 Botucatu Trophoblastic Disease Center of the Clinical Hospital of Botucatu Medical School, Department of Gynecology and Obstetrics, São Paulo State University Julio de Mesquita Filho - UNESP, Botucatu, SP, Brazil
4 Carlos G Durand Hospital Trophoblastic Disease Center, Faculty of Medicine, Universidad de Buenos Aires, Buenos Aires, Argentina
5 Oncólogos del Occidente S.A. Manizales, Caldas, Colombia
6 Department of Obstetrics and Gynecology, Hospital Universitario de Caracas, Universidad Central de Venezuela, Caracas, Venezuela
7 Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, New England Trophoblastic Disease Centre, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States
8 Trophoblastic Tumour Screening and Treatment Centre, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom

Rev Bras Ginecol Obstet 2022;44(8):746–754.

Abstract

Objective There are few multinational studies on gestational trophoblastic neoplasia (GTN) treatment outcomes in South America. The purpose of this study was to assess the clinical presentation, treatment outcomes, and factors associated with chemoresistance in low-risk postmolar GTN treated with first-line single-agent chemotherapy in three South American centers.

Methods Multicentric, historical cohort study including women with International Federation of Gynecology and Obstetrics (FIGO)-staged low-risk postmolar GTN attending centers in Argentina, Brazil, and Colombia between 1990 and 2014. Data were obtained on patient characteristics, disease presentation, and treatment response. Logistic regression was used to assess the relationship between clinical factors...
Introduction

Gestational trophoblastic neoplasia (GTN) is a malignant form of gestational trophoblastic disease with abnormal proliferation of placental trophoblastic cells that secrete persistent amounts of human chorionic gonadotropin (hCG). The clinical presentation of GTN is variable depending on previous pregnancy type, disease extension and histopathological classification. Invasive mole and choriocarcinoma are very responsive to chemotherapy, and hCG values are usually well correlated with the volume of disease. On the other hand, placental site trophoblastic tumor and epithelioid trophoblastic tumor are resistance to first-line single-agent treatment. A multivariate analysis of the clinical factors significant in univariate analysis was performed.

Results

A total of 163 women with low-risk GTN were included in the analysis. The overall rate of complete response to first-line chemotherapy was 80% (130/163). The rates of complete response to methotrexate or actinomycin-D as first-line treatment, and actinomycin-D as second-line treatment postmethotrexate failure were 79% (125/157), 83% (%), and 70% (23/33), respectively. Switching to second-line treatment due to chemoresistance occurred in 20.2% of cases (33/163). The multivariate analysis demonstrated that patients with a 5 to 6 FIGO risk score were 4.2-fold more likely to develop resistance to first-line single-agent treatment ($p = 0.019$).

Conclusion

1) At presentation, most women showed clinical characteristics favorable to a good outcome, 2) the overall rate of sustained complete remission after first-line single-agent treatment was comparable to that observed in developed countries, 3) a FIGO risk score of 5 or 6 is associated with development of resistance to first-line single-agent chemotherapy.
relatively chemoresistant and produce less hCG compared with other forms of GTN. In these cases, surgery is often the treatment of choice.6

Gestational trophoblastic neoplasia can occur after any type of pregnancy. However, the risk of developing GTN is highest in women with a molar pregnancy. In fact, between 50 and 80% of all GTN cases originate from a hydatidiform mole, and the remainder from a term/preterm pregnancy, miscarriage, or ectopic pregnancy.6 Between 15 and 20% of patients with a complete hydatidiform mole (CHM) and 1 to 4% of those with a partial mole develop postmolar GTN. These rates may differ from region to region, possibly reflecting differences in the hCG assays and criteria used for the diagnosis of GTN, or even unavailability of demographic data on the entire population.

Gestational trophoblastic neoplasia cure rates are over 90% overall and above 99% in some countries. These good results can be explained by the adequate use of hCG as a biomarker, provision of patient care in specialized centers, identification of prognostic factors for chemotherapy response, and availability of active second- and third-line chemotherapy regimens. In 2000, the International Federation of Gynecology and Obstetrics and the International Society of Gynecological Cancer (FIGO Oncology Committee, 2002) established a combined anatomic staging (stages I, II, III, and IV) and modified World Health Organization (WHO) risk-factor scoring system for classifying GTN as low (<7) or high (≥7) risk for the development of resistance to single-agent chemotherapy.

First-line chemotherapy with either methotrexate (MTX) or actinomycin D (ActD) is the treatment of choice worldwide for patients with low-risk postmolar GTN (score <7).7 The most commonly used chemotherapy regimens are MTX (intravenous [IV] or IM), maximum of 25 mg/m2 daily for 5 days repeated every 2 weeks; 50 mg MTX for 8 days (IM) on days 1, 3, 5, and 7, and with folinic acid (FA) rescue (0.1 mg/kg) on days 2, 4, 6, and 8; ActD 1.25 mg/m2 (maximum of 2 mg) single IV dose every 2 weeks; and ActD 10 to 12 µg/kg IV for 5 days every 2 weeks.8 It is important to emphasize that prompt chemotherapy treatment with appropriate regimens and fixed and timely intervals between chemotherapy cycles limits the development of resistance and the exposure of most patients to multi-agent chemotherapy.9,10

There are few studies on GTN treatment response in South American patients, and most of them are single-center, hospital-based.11 The difficulties in carrying out multicentric studies in South American countries include socioeconomic and cultural diversities, as well as language barriers (Portuguese, Spanish, English). Given these disparities, the assessment of whether the results of first-line treatment with a single agent are similar or different from those observed in specialized centers in developed countries is relevant. Therefore, the purpose of this study was to assess the clinical presentation, treatment outcomes, and factors associated with chemoresistance in South American patients with low-risk postmolar GTN treated with first-line single-agent chemotherapy.

Methods

This historical, multicentric, cohort study included women with FIGO-defined low-risk postmolar GTN treated from 1990 to 2014 at one of the following South American centers: Centro de Doenças Trofoblásticas de Botucatu, Universidade Estadual de São Paulo—Unesp, São Paulo, Brazil; Durand Trophoblastic Diseases Center in Buenos Aires, Hospital Carlos G. Durand, Buenos Aires, Argentina; and Oncologists del Occidente S.A. Manizales, Caldas, Colombia. These three centers provide tertiary care and consultation free of charge.

In all study participants, metastases were detected by clinical, gynecological, and imaging examinations. First, transvaginal power Doppler sonography was performed to rule out the presence of pregnancy and residual molar tissue, and to assess the myometrium for invasion and pelvic mass vascularity. A chest X-ray including at least two views (posterior-anterior and lateral) was used to count lung metastases and FIGO scoring. When chest X-rays were normal, no further imaging was ordered, and treatment was promptly indicated. For patients with genital metastases, suspected lung metastasis on chest X-ray, or nodules > 1 cm, a chest tomography was conducted to determine the extent of disease in the lungs. At each of the three participating centers, images of lung metastases were reviewed, and metastatic nodules ≥ 1 cm were counted. Metastases at other sites were investigated as described elsewhere.

The hCG tests used for monitoring response to treatment were Abbott Architect (Centro de Doenças Trofoblásticas de Botucatu) and Roche Elecsys (Durand Trophoblastic Disease Center). At Oncologists del Occidente S.A., kits by different manufacturers were used (Abbott Architect, Roche Elecsys, Siemens Immulite). However, all hCG tests for each individual patient were performed at the same laboratory to avoid variation among methods and results.

Participants received first-line chemotherapy with 8-day MTX/FA with FA rescue (0.1 mg/kg or 15 mg fixed dose) or ActD as a 2-week cycle. Multiple cycles of the same chemotherapy regimen were given until hCG remission, resistance development, or substantial toxicity (grades 3–4) was reached. Consolidation chemotherapy was administered using the last effective regimen as one cycle to all patients in Argentina, while in Brazil and Colombia, two consolidations cycles were given for stage II or III cases. Patients were advised to use oral contraception throughout GTN treatment and follow up.

Remission was defined as 3 normal consecutive serum hCG measurements (<5 IU/L for Brazil and Colombia; <2 IU/L for Argentina) taken every 1 to 2 weeks. Cure or sustained complete remission was declared when normal values of hCG were observed for at least 12 months after remission was achieved. Resistance was determined by a hCG plateau of ± 10% over 2 weeks or re-elevation in at least one
measurement of the hCG level while the patient was on first-line treatment with MTX or ActD. Second-line treatment consisted of switching the first single agent used (MTX as first-line switched for ActD as second line and vice versa) or capecitabine. All patients either resistant to MTX or with MTX toxicity were eligible for ActD or capecitabine second-line therapy. Two patients received etoposide due to ActD unavailability, and three were given multiagent chemotherapy due to a higher FIGO score (score of 6) or hCG $>30,000$ IU/L at the point of resistance to first-line single agent therapy.

The medical records (paper and electronic) of all patients with low-risk postmolar GTN (stages I–III, score < 7) were reviewed. Data on patient characteristics, disease presentation, and treatment response were obtained.

Patient and disease characteristics were assessed based on age, gravidity, parity, molar histology (complete or partial), time between molar evacuation and postmolar GTN diagnosis, interval between GTN diagnosis and chemotherapy initiation, hCG before first-line chemotherapy, presence of metastatic disease, and FIGO stage/risk score.

Response to first-line treatment with MTX or ActD was investigated using the following variables: number of first-line chemotherapy cycles, total number of chemotherapy cycles required to achieve remission, time to remission (interval between first-line chemotherapy initiation and first normal hCG), need for switching to second-line chemotherapy due to resistance to first-line treatment, or occurrence of substantial toxicity, surgery after chemoresponse, and survival rate.

This study was approved by the Research Ethics Committees of all participating institutions.

Statistical analyses were performed using the IBM SPSS Statistics for Windows, version 21.0 software (IBM Corp., Armonk, NY, USA). Univariate analysis was used to assess the associations between clinical factors and resistance to single agent first-line treatment. A multiple logistic regression model was fit to evaluate the associations of resistance to single agent first-line treatment with the clinical factors considered significant ($p < 0.20$) on univariate analysis. Associations were considered significant when $p < 0.05$.

This study was approved by the ethics committee of the Botucatu Medical School of Universidade Estadual de São Paulo, under protocol no. 563.812 (CAAE 17817613.6.0000.5411), Comité de Bioética Hospital General de Aguad Estadual de Sao Paulo, and Comité de Ética de Investigación de Oncologistas del Occidente (IC-FO-003).

Results

Of 233 women diagnosed with FIGO-defined low-risk postmolar GTN, 163 received single agent first-line treatment with either MTX or ActD and were included in the analysis. The remaining 70 women were excluded for the following reasons: first-line treatment with chemotherapy agents other than MTX and ACTD ($n = 13$), initial treatment outside the study Center ($n = 8$), primary hysterectomy ($n = 8$), missing data ($n = 15$), and loss to follow-up < 12 months after serum hCG normalization ($n = 23$) (–Fig. 1). The clinical characteristics of the 163 study participants with low-risk postmolar GTN are shown in –Table 1. The median age (1st, 3rd quartile) of patients was 28 years (21, 33 years) and the median parity (1st, 3rd quartile) was 1 (0, 1).

Complete hydatidiform mole was the most frequently
The following single-agent chemotherapy regimens were administered: 8-day MTX/FA (n = 142), 5-day MTX (n = 15), pulsed ActD (n = 1), or 5-day ActD (n = 5). Of note, the median interval between GTN diagnosis and initiation of single-agent first-line treatment (1st, 3rd quartile) was 2 days (0–6). The median number of cycles (1st, 3rd quartile) given until hCG normalization or first-line agent resistance was 4 (3, 7). The rates of sustained complete remission with MTX or ActD as first-line treatment were 79.6% (125/157) and 83.3% (9), respectively. Among the 33 patients (20.2%) requiring a switch to second-line treatment, 24 received ActD, 4 capcitabine, 2 etoposide, and 3 multi-agent chemotherapy. Failure of second-line single-agent treatment was observed in only 2 patients (1.2%), 1 with 5-day ActD, and the other with capcitabine, who required multiagent chemotherapy to achieve complete remission. Surgery after chemotherapy was performed in 6.7% of patients (9 underwent hysterectomy, and 2 local uterine resection). The median time (1st, 3rd quartile) to reach hCG normalization was 12 weeks (7.7, 19). Gestational trophoblastic neoplasia patients with FIGO risk score 5 to 6 that achieved remission after first- or second-line single-agent chemotherapy accounted for 90.5% (19/21) of the study population (Table 1).

Two patients experienced substantial toxicity during first-line treatment (grade 3 oral mucositis in 1 patient who received 5-day-MTX, and grade 3 nausea/vomiting in 1 patient who received 5-day ActD). However, no failure in first-line single-agent treatment due to chemotherapy-induced toxicity was observed. In these cases, chemotherapy was discontinued, and, because hCG normalization was reached while the patients were recovering from toxicity, chemotherapy was no longer used. All study participants were followed up for at least 12 months after completing chemotherapy. Survival rate between low-risk GTN diagnosis and the end of follow-up was 100% (Table 1).

Univariate analysis showed that a FIGO risk score of 5 to 6 (odds ratio [OR] = 5.75 [95% CI 2.03–16.31], p = 0.001), total number of chemotherapy cycles required to achieve remission (1.32 [1.16–1.49], p < 0.001), and time to remission (1.07 [1.03–1.11], p = 0.001) were identified as significant indicators of resistance to first-line single-agent treatment (Table 2). Multivariate analysis, including the clinical factors considered significant on univariate analysis, demonstrated that patients with a FIGO risk score of 5 to 6 were 4.2-fold more likely to develop resistance to first-line single-agent treatment (p = 0.019). Among the patients with a 5 to 6 FIGO score, the rate of chemoresistance to first-line treatment was 52.4% (11/21), whereas in those with a FIGO risk score of 0 to 2 and 3 to 4, it was 16% (13/81) and 14.8% (9/61), respectively.

**Table 1** Patient and disease characteristics (n = 163)

| Variables                        | Summary               |
|----------------------------------|-----------------------|
| Age (years)                      | 28.0 (21.0, 33.0)     |
| Gravidity                        | 2.0 (1.0, 3.0)        |
| Parity                           | 1.0 (0.0, 1.0)        |
| Molar histology                  |                       |
| Partial                          | 27 (16.6%)            |
| Complete                         | 136 (83.4%)           |
| HM evacuation-GTN diagnosis interval (months) | 2.3 (1.6, 3.6)        |
| GTN diagnosis-chemotherapy initiation interval (days) | 2.0 (0.0–6.0)         |
| Pre-treatment hCG                | 7,442 (1,693, 29,227) |
| Pre-treatment hCG < 1,000         | 31 (19.0%)            |
| 1,000 < 10,000                   | 60 (36.8%)            |
| 10,000–99,999                    | 62 (38.0%)            |
| ≥ 100,000                        | 10 (6.2%)             |
| Metastatic disease at presentation | 51 (31.2%)           |
| FIGO stage                       |                       |
| 1                                | 112 (68.7%)           |
| 2                                | 3 (1.8%)              |
| 3                                | 48 (29.4%)            |
| FIGO risk score                  | 3.0 (1.0, 4.0)        |
| FIGO risk score 0–2              | 81 (49.7%)            |
| 3–4                              | 61 (37.5%)            |
| 5–6                              | 21 (12.8%)            |
| Number of first-line chemotherapy cycles | 4.0 (3.0, 7.0)      |
| Total number of chemotherapy cycles to remission | 5.0 (3.0–8.0)       |
| Time to hCG remission (weeks)    | 12.5 (7.7, 19.0)      |
| Switch to second-line treatment  | 33 (20.2%)            |
| Switch to third-line treatment   | 2 (1.2%)              |
| Surgery after chemoresistance    | 11 (6.74%)            |
| Survival rate                    | 163 (100.0%)          |

Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; GTN, gestational trophoblastic neoplasia; hCG, human chorionic gonadotropin; M, hydatiform mole.

Data are median (25th–75th percentile) or n (%).

Discussion

This study including South American women with low-risk postmolar GTN showed that most patients had clinical characteristics favorable to a successful response to treatment. The overall rate of sustained complete remission after first-line single-agent treatment was ~ 80%, and high FIGO scores (5–6) were strongly associated with resistance to first-line single-agent therapy.
The rates of sustained complete remission with MTX or ActD as first-line treatment were similar to those reported in developed countries\textsuperscript{9,13,14,21} and other specialized South American centers as well.\textsuperscript{16,18} The excellent overall cure rate found in our study is likely to be explained by the fact that our patients were initially treated in specialized centers. These provide interdisciplinary care, give each patient and their families the information needed to understand the disease and foster awareness of the importance of regular hCG monitoring, as well as actively identifying and recalling patients who miss appointments.\textsuperscript{22} These centers perform GTN staging within 1 day after diagnosis so that prompt chemotherapeutic treatment can be started as recommended.\textsuperscript{23} Additionally, these centers provide uninsured patients with medical care and chemotherapy drugs free of charge.\textsuperscript{17} However, it is worth noting that specialized centers are not found in all Latin American countries, where the time elapsed between GTN diagnosis and treatment initiation is influenced by socioeconomic factors and health policies that do not always prioritize treatment for a rare condition such as GTN.\textsuperscript{19} Centralized hCG monitoring has been recommended after molar evacuation, but this is not yet feasible in all countries and regions of South America. Therefore, training physicians for patient referral to a specialized center as soon as hCG plateaus or rises is essential to allow the prompt start of chemotherapy to patients with lower FIGO risk scores (< 5) to quickly achieve therapeutic success.\textsuperscript{5,19}

In the majority of our patients, disease duration was less than 4 months, serum hCG level was within the lower range, FIGO risk score was < 5, and the interval between GTN diagnosis and initiation of first-line single agent treatment was short, allowing an excellent response to treatment. Indeed, previous reports have demonstrated that, in women with GTN followed up at specialized centers after molar evacuation, median FIGO risk score is lower and median time interval between molar evacuation and chemotherapy initiation is shorter than in those initially treated in other institutions.\textsuperscript{24}

In our patients, treated with either MTX or ActD, the rate of switching to second-line therapy due to the development of resistance to first-line treatment was comparable to those reported with the use of MTX\textsuperscript{9,21} and ActD as first-line therapy.\textsuperscript{25}

The single-agent ActD regimen has been reported to provide a higher complete remission rate than MTX.\textsuperscript{26} However, MTX has been demonstrated to have a more favorable toxicity profile,\textsuperscript{18} as it causes no alopecia and has no vesicant properties and reduced risk of vascular disorders, which have all been associated with ActD, particularly the 5-day regimen.\textsuperscript{27} These data, added to the fact that ActD is not always

---

**Table 2** Univariate associations of resistance to first-line chemotherapy with clinical factors

| Variables                              | OR     | 95% CI   | P     |
|----------------------------------------|--------|----------|-------|
| Age (years)                            | 0.98   | 0.94     | 1.03  | 0.488 |
| Gravidity                              | 0.79   | 0.58     | 1.08  | 0.146 |
| Parity                                 | 0.80   | 0.55     | 1.18  | 0.260 |
| Complete mole                          | 0.87   | 0.32     | 2.36  | 0.780 |
| HM evacuation - GTN diagnosis interval (months) | 0.97   | 0.82     | 1.16  | 0.740 |
| GTN diagnosis-chemotherapy initiation interval (days) | 0.97 | 0.92 | 1.03 | 0.327 |
| Pretreatment hCG                       | 1.00   | 1.00     | 1.00  | 0.020 |
| Pretreatment hCG (Reference ≤ 1,000)   |        |          |       | 0.140 |
| [1,000–10,000)                         | 0.45   | 0.14     | 1.43  | 0.178 |
| [10,000–100,000)                       | 1.09   | 0.39     | 3.04  | 0.863 |
| ≥ 100,000                             | 2.29   | 0.50     | 10.45 | 0.286 |
| Metastatic disease at presentation     | 1.26   | 0.55     | 2.85  | 0.584 |
| FIGO stage (reference = 1)             |        |          |       | 0.715 |
| 2                                     | 2.17   | 0.19     | 25.03 | 0.536 |
| 3                                     | 1.29   | 0.57     | 2.94  | 0.547 |
| FIGO risk score                       | 1.43   | 1.10     | 1.86  | 0.007 |
| FIGO risk score (reference = 0–2)      |        |          |       |       |
| 3–4                                   | 0.91   | 0.36     | 2.28  | 0.833 |
| 5–6                                   | 5.75   | 2.03     | 16.31 | 0.001 |
| Number of first-line chemotherapy cycles | 1.05  | 0.54     | 1.17  | 0.405 |
| Total number of chemotherapy cycles to remission | 1.32  | 1.16 | 1.49 | < 0.001 |
| Time to hCG remission (weeks)         | 1.07   | 1.03     | 1.11  | 0.001 |

Abbreviations: CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; GTN, gestational trophoblastic neoplasia; hCG, human chorionic gonadotropin; HM, hydatidiform mole; OR, odds ratio.
available, have made multi-course MTX and rescue with folinic acid the most commonly used regimen in Latin America, where it is administered in an outpatient setting.\textsuperscript{16,18,19,28} Multivariate analysis revealed that our patients with FIGO risk score of 5 to 6 are significantly more likely to develop resistance to first-line single-agent treatment. This is in line with other reports that show that around 70\% of patients in this subset become chemo-resistant, and that this is directly related to chemotherapy duration and need for switching to a subsequent more toxic treatment.\textsuperscript{1} Notably, all our patients who experienced treatment failure with first-line single-agent chemotherapy were cured with sequential single-agent chemotherapy or multiagent chemotherapy with or without the use of salvage surgery.

Several previous investigations have identified pretreatment hCG > 100,000 IU/L\textsuperscript{29} uterine artery pulsatility index < 1,\textsuperscript{30} and presence of lung metastases\textsuperscript{31} as predictive of resistance to first-line therapy in women with low-risk GTN. However, none of these resistance predictors have been validated.\textsuperscript{3} The largest international collaborative study of GTN patients with a FIGO score of 5 to 6 to date\textsuperscript{4} reveals that metastatic disease, choriocarcinoma, and pretreatment hCG concentration are significant predictors of resistance to single-agent therapies among these women.\textsuperscript{4} However, in our study, FIGO score 5 to 6 was the only factor to reach statistical significance. The fact that hCG at diagnosis was < 100,000 IU/L in the great majority of our patients might explain this finding.

Despite being multicentric, this study is limited by the inherent bias introduced by its retrospective hospital-based design which affect the generalizability of our results. It is noteworthy that the participating centers used different hCG cutoffs to define remission, but this did not affect the assessment of chemo-resistance incidence. Other limitations included the small sample size (especially in the scenarios of risk factors for chemotherapy resistance in case of low-risk GTN FIGO risk score of 5–6), and the fact that different first- and second-line regimens were used at the study centers. Additionally, although present in some studies used for comparison, factors related to chemoresistance in low-risk GTN, such as presence of choriocarcinoma, antecedent miscarriage, preterm/term gestation, and ectopic pregnancy, were not addressed herein. Nonetheless, the power of our multivariate analysis on the occurrence of resistance to first-line single-agent treatment was over 95%.

This is the first study to describe low-risk GTN clinical presentation, remission rates, treatment outcomes and resistance risk in South American gestational trophoblastic centers. Our findings may be useful to physicians in guiding decision-making, as they indicate which patients are at a higher risk of resistance and should, therefore, be referred to a specialized center upfront. This can contribute to improve the quality of life of the patients by decreasing exposure to more toxic multiagent therapy and increasing their chance to achieve complete remission more quickly.

Conclusion

In brief, this study of South American women with low-risk of GTN treated in specialized centers led to the following conclusions: 1) at presentation, most patients showed clinical characteristics favorable for a good outcome, 2) the overall rate of sustained complete remission observed after first-line single-agent treatment was comparable to that of developed countries, 3) FIGO risk scores of 5 or 6 are associated with the development of resistance to first-line single-agent chemotherapy.

Contributions

L. A. C. R. conceived and designed the study, reviewed the literature, and collected and managed data from the databases of Durand Trophoblastic Disease Center in Buenos Aires (Carlos G. Durand Hospital), Botucatu Trophoblastic Disease Center (São Paulo State University), and Oncólogos del Occidente S. A. Manizales, Caldas, Colombia; wrote the initial draft of the manuscript. I. M. conceived and designed the study, wrote the manuscript and audited data collected from Botucatu Trophoblastic Disease Center database (São Paulo State University) by L. A. C. R. M. I. B. audited the data collected by L. A. C. R. from the Durand Trophoblastic Disease Center database in Buenos Aires (Carlos G. Durand Hospital) and contributed to data analysis. G. J. helped analyzing data from the Durand Trophoblastic Disease Center database in Buenos Aires (Carlos G. Durand Hospital) and contributed to the manuscript. S. O. helped with the analysis of data from the Carlos G. Durand Hospital database and contributed to the manuscript. C. R. V. M. audited data collected by L. A. C. R. from the database of Oncólogos del Occidente S. A. Manizales, Caldas, Colombia and contributed to the manuscript. R. C. C. contributed to data analysis and interpretation and reviewed the literature for discussion. K. M. E. conceived the analysis strategy and contributed to the manuscript. N. S. H. contributed to data analysis and interpretation and revised the manuscript. M. J. S. supervised the study and revised the manuscript. R. S. B. supervised the study and revised the manuscript.

Conflict of Interests

The authors have no conflict of interests to declare.

Acknowledgments

The authors are thankful to Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil, the International Research Networks (IRN) under Universidade Estadual de São Paulo - UNESP’s CAPES-PrInt PROJECT/HEALTH AND WELLBEING, and the Donald P. Goldstein, MD Trophoblastic Tumor Registry Endowment, and the Dyett Family Trophoblastic Disease Research and Registry Endowment for their support and assistance in consolidating international collaboration among institutions through the exchange of researchers. This study received financial support from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil.
(Research Networks under UNESP’s CAPES-PrInt PROJECT/HEALTH AND WELLBEING) – [Finance Code 001 (IM); CAPES-PrInt – AUXPE Finance Code 88881.310509/2018-01] as well as from the Donald P. Goldstein, MD Trophoblastic Tumor Registry Endowment and the Dyett Family Trophoblastic Disease Research and Registry Endowment. The funding agencies had no role in the design, interpretation of the data, or the manuscript writing.

References

1 Sita-Lumsden A, Sebire NJ, Lindsay I, Seckl MJ, Goldstein DP, Winig P, Shirley RL. Actinomycin D as initial therapy for low-risk gestational trophoblastic neoplasia. Br J Obstet Gynaecol. 2000;107(11):1810–1814. DOI: 10.1088/bjog.2012.462

2 Hancock BW, Tidy J. Placental site trophoblastic tumour and epithelioid trophoblastic tumour. Best Pract Res Clin Obstet Gynaecol. 2021;74:131–148. DOI: 10.1016/j.bpobgyn.2020.10.004

3 Elias KM, Berkowitz RS, Horowitz NS. State-of-the-art workup and initial management of newly diagnosed molar pregnancy and postmolar gestational trophoblastic neoplasia. J Natl Compr Canc Netw. 2019;17(11):1396–1401. DOI: 10.6040/jncnm.2019.7364

4 Braga A, Paiva G, Ghorani E, Freitas F, Velarde LG, Kaur B, et al. Predictors for single-agent resistance in FIGO stage 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study. Lancet Oncol. 2021;22(08):1188–1198. DOI: 10.1016/S1470-2045(21)00262-X

5 Seckl MJ, Ghorani E. Progress to international harmonisation of care and future developments. Best Pract Res Clin Obstet Gynaecol. 2021;74:159–167. DOI: 10.1016/j.bpobgyn.2021.05.006

6 Freitas F, Braga A, Viggiano M, Velarde LD, Maesta I, Uberti E, et al. Gestational trophoblastic neoplasia lethality among Brazilian women: A retrospective national cohort study. Gynecol Oncol. 2020;158(02):452–459. DOI: 10.1016/j.ygyno.2020.04.074

7 Seckl MJ, Sebire NJ, Fisher RA, Golffer F, Massuger L, Sessa CESMO Guidelines Working Group. Gestational trophoblastic disease: ESfMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi39–vi50. DOI: 10.1093/annonc/mdt345

8 FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. Int J Gynaecol Obstet. 2002;77(03):285–287. DOI: 10.1016/S0020-7292(02)00063-2

9 Chapman-Davis E, Hoekstra AV, Rademaker AW, Schink JC, Lurain JR. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy. Gynecol Oncol. 2012;125(03):572–575. DOI: 10.1016/j.ygyno.2012.03.039

10 Berkowitz RS, Goldstein DP, Bernstein MR. Ten year’s experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. Gynecol Oncol. 1986;23(01):111–118. DOI: 10.1016/0090-8258(86)90123-x

11 Petrelli ES, Twigg BS, Blessing JA, Teng NH, Curry S. Single-dose actinomycin-D treatment for nonmetastatic gestational trophoblastic disease. A prospective phase II trial of the Gynecologic Oncology Group. Cancer. 1987;60(09):2173–2176. DOI: 10.1002/1097-0142(19871101)60:9<2173::AID-CNCR2820609103>3.0.CO;2-3

12 Goldstein DP, Wing P, Shirley RL. Actinomycin D as initial therapy of gestational trophoblastic disease: A reevaluation. Obstet Gynecol. 1972;39(03):341–345

13 Sita-Lumsden A, Short D, Lindsay I, Sebire NJ, Adjogatse D, Seckl MJ, et al. Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009. Br J Cancer. 2012;107(11):1810–1814. DOI: 10.1038/bjc.2012.462

14 Cortés-Charry R, Hennah L, Froeling FE, Short D, Aguiar X, Tin T, et al. Increasing the human chorionic gonadotrophin cut-off to ≤1000 IU/L for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapy. ESMO Open. 2021;6(03):100110. DOI: 10.1016/j.esmoop.2021.100110

15 Bianconi MI, Otero S, Moscheni O, Alvarez L, Storino C, Jankilevich G. Gestational trophoblastic disease: a 21-year review of the clinical experience at an Argentinean public hospital. J Reprod Med. 2012;57(7-8):341–349

16 Uberti EM, Fajardo MdoC, da Cunha AG, Frota SS, Braga A, Ayub AC. Treatment of low-risk gestational trophoblastic neoplasia comparing biweekly eight-day Methotrexate with folinic acid versus bolus-dose Actinomycin-D, among Brazilian women. Rev Bras Ginecol Obstet. 2015;37(06):258–265. DOI: 10.1590/S0100-720320150005366

17 Maéstá I, de Freitas Segalla Moreira M, Rezende-Filho J, Bianconi MI, Jankilevich G, Otero S, et al. Outcomes in the management of high-risk gestational trophoblastic neoplasia in trophoblastic disease centers in South America. Int J Gynecol Cancer. 2020;30(09):1366–1371. DOI: 10.1136/ijgc-2020-001237

18 Poli JC, Paiva G, Freitas F, Mora P, Velarde LG, Amim Jr, et al. Folinic acid rescue during methotrexate treatment for low-risk gestational trophoblastic neoplasia – How much is just right? Gynecol Oncol. 2021;162(03):638–644. DOI: 10.1016/j.ygyno.2021.07.013

19 Cortés-Charry R, Maéstá I, Bianconi MI. Presentation and management of molar pregnancy and gestational trophoblastic neoplasia in Latin America. In: Hancock BW, Seckl MJ, Berkowitz RS, editors. Gestational trophoblastic disease. 4th ed. Orange: International Society for the Study of Trophoblastic Diseases; 2015. p. 1–15.

20 Dantas PR, Maéstá I, Filho JR, Amin Junior J, Elias KM, Horowitz N, et al. Does hormonal contraception during molar pregnancy follow-up influence the risk and clinical aggressiveness of gestational trophoblastic neoplasia after controlling for risk factors? Gynecol Oncol. 2017;147(02):364–370. DOI: 10.1016/j.ygyno.2017.09.007

21 Maéstá I, Nitecki R, Horowitz NS, Goldstein PP, Moreira MF, Elias KM, et al. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience. Gynecol Oncol. 2018;148(01):161–167. DOI: 10.1016/j.ygyno.2017.10.028

22 Ferreira EG, Maéstá I, Michelin OC, de Paula RC, Consomni M, Rudge MV. Assessment of quality of life and psychologic aspects in patients with gestational trophoblastic disease. J Reprod Med. 2009;54(04):239–244

23 Lok C, van Trommel N, Massuger L, Golffer F, Seckl MClinical Working Party of the EOTTD. Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease. Eur J Cancer. 2020;130:238–240. DOI: 10.1016/j.ejca.2020.02.011

24 Dantas PR, Maéstá I, Cortés-Charry R, Growdon WB, Braga A, Rudge MV, et al. Influence of hydatidiform mole follow-up setting on postmolar gestational trophoblastic neoplasia outcomes: a cohort study. J Reprod Med. 2012;57(7-8):305–309

25 Hoskins PJ, Le N, Kumar A, Pina A, Sabourin JN, Kim H, et al. Single or two combination therapy as initial treatment for low risk, gestational trophoblastic neoplasia. A Canadian analysis. Gynecol Oncol. 2020;157(02):367–371. DOI: 10.1016/j.ygyno.2020.02.005

26 Osborne RJ, Filicai V, Schink JC, Mannel RS, Alvarez SecordA, Kelley JL, et al. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol. 2011;29(07):825–831. DOI: 10.1200/JCO.2010.30.4386
Maestá I, Nitecki R, Desmarais CCF, Horowitz NS, Goldstein DP, Elias KM, et al. Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2020;157(02):372–378. Doi: 10.1016/j.ygyno.2020.02.001

Mora PAR, Sun SY, Velarde GC, Rezende Filho J, Uberti EH, Esteves AP, et al. Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia? Gynecol Oncol. 2019;153(02):277–285. Doi: 10.1016/j.ygyno.2019.03.005

McGrath S, Short D, Harvey R, Schmid P, Savage PM, Seckl MJ. The management and outcome of women with post-hydantidiform mole ‘low-risk’ gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1). Br J Cancer. 2010;102(05):810–814. Doi: 10.1038/sj.bjc.6605529

Sita-Lumsden A, Medani H, Fisher R, Harvey R, Short D, Sebire N, et al. Uterine artery pulsatility index improves prediction of methotrexate resistance in women with gestational trophoblastic neoplasia with FIGO score 5-6. BJOG. 2013;120(08):1012–1015. Doi: 10.1111/1471-0528.12196

Frijstein MM, Lok C, van Trommel NE, Ten Kate Booij MJ, Massuger L, van Werkhoven E, et al. Lung metastases in low-risk gestational trophoblastic neoplasia: a retrospective cohort study. BJOG. 2020;127(03):389–395. Doi: 10.1111/1471-0528.16036